SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-089091
Filing Date
2024-04-08
Accepted
2024-04-08 06:44:01
Documents
14
Period of Report
2024-04-08
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d757694d8k.htm   iXBRL 8-K 55416
2 EX-99.1 d757694dex991.htm EX-99.1 44775
  Complete submission text file 0001193125-24-089091.txt   243266

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inzy-20240408.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inzy-20240408_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inzy-20240408_pre.xml EX-101.PRE 11707
17 EXTRACTED XBRL INSTANCE DOCUMENT d757694d8k_htm.xml XML 3762
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 24828139
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)